The final, formatted version of the article will be published soon.
CASE REPORT article
Front. Endocrinol.
Sec. Bone Research
Volume 15 - 2024 |
doi: 10.3389/fendo.2024.1359975
18F-AlF-NOTA-Octreotide PET/CT and 3D printing technology for precision diagnosis and treatment of phosphaturic mesenchymal tumors in patients with tumor-induced osteomalacia: Two case reports
Provisionally accepted- 1 Department of Orthopedics and Trauma, Weifang People's Hospital (First Affiliated Hospital of Shandong Second Medical University), Weifang, Shandong Province, China
- 2 Weifang stomatology Hospital, Weifang, China
- 3 Department of Pathology, Weifang People's Hospital (First Affiliated Hospital of Shandong Second Medical University), Weifang, China
- 4 College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China
Objective: This study aims to report the application of 18F-AlF-NOTA-Octreotide PET/CT and 3D printing technology in the diagnosis and treatment of phosphaturic mesenchymal tumors (PMT) in patients with tumor-induced osteomalacia (TIO). Case presentation: A 68-year-old male patient (Case 1) was admitted to the Weifang People’s Hospital in August 2022 with complaints of “persistent pain in the bilateral flank and lumbosacral region”. 18F-AlF-NOTA-Octreotide PET/CT showed high octreotide expression in the left femoral region. A 48-year-old male patient (Case 2) was admitted to the Weifang People’s Hospital in November 2022, complaining of “pain in the lumbar region and ribs”. 18F-AlF-NOTA-Octreotide PET/CT showed high octreotide expression in the pancreatic uncinate process and the left acetabulum. They were diagnosed with hypophosphatemic osteomalacia, with a strong consideration of an underlying neuroendocrine tumor. Preoperative design of 3D virtual surgery, CAD/CAM, and 3D printing technology were used to customize the digital surgical guide plates, and the surgery was carried out. They were both finally confirmed as phosphateuric mesenchymal tumors (PMT) based on postoperative pathology and immunohistochemistry results. Both patients experienced substantial relief from their clinical manifestations after surgery. Conclusion: 18F-AlF-NOTA-Octreotide PET/CT may be a precise diagnostic method for TIO, while 3D printing technology may serve as an effective and dependable adjunct for the treatment of PMT in patients with TIO.
Keywords: Phosphaturic mesenchymal tumors, Tumor-induced osteomalacia, 18F-AlF-NOTA-Octreotide PET/CT imaging, 3D printing technology, case reports
Received: 22 Dec 2023; Accepted: 31 Oct 2024.
Copyright: © 2024 Zhao, Guan, Zhang, Shi, Luo, Yang, Wang, Liu, Liu, Ding and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jie Zhao, Department of Orthopedics and Trauma, Weifang People's Hospital (First Affiliated Hospital of Shandong Second Medical University), Weifang, Shandong Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.